¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immediately dangerous to life concentration"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • life instinct
    »îº»´É, »ýº»´É
  • life line
    1. »ý¸íÀüÈ­ 2. »ý¸í±¸Á¶¼±
  • life style disease
    »ýȰ½À°üº´
  • life table
    »ý¸íÇ¥
  • mean life expectancy
    Æò±Õ¿©¸í
  • mean life span
    Æò±Õ¼ö¸í
  • sylvatic life cycle
    ¾ß»ý»ýȰÁÖ±â
  • shelf life
    ÀúÀå±â°£, º¸°ü±â°£
  • blood concentration
    Ç÷Áß³óµµ
  • concentration
    1. ³óÃà 2. ³óµµ 3. ÁýÁß
  • concentration effect
    ³óµµÈ¿°ú
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
  • critical micelle concentration
    ÀÓ°è¹Ì¼¿³óµµ, ÀÓ°èÀ¯È­¸³³óµµ
  • egg concentration technique
    Áý¶õ¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intrauterine life
    Àڱó»»ýȰ
  • life instinct
    »îº»´É, »ýº»´É
  • life
    »ýȰ
  • life annuity
    Á¾½Å¿¬±Ý
  • life expectancy
    ±â´ë¿©¸í
  • life line
    »ý¸íÀüÈ­, »ý¸í±¸Á¶¼±
  • life table
    »ý¸íÇ¥
  • life insurance medicine
    »ý¸íº¸ÇèÀÇÇÐ
  • life insurance method
    »ý¸íº¸Çè¹ý
  • physical half life
    ¹°¸®Àû¹Ý°¨±â
  • shelf life
    ÀúÀå±â°£, º¸°ü±â°£
  • mean life span
    Æò±Õ¼ö¸í
  • blood concentration
    Ç÷Áß³óµµ
  • concentration
    ³óµµ, ÁýÁß
  • concentration effect
    ³óµµÈ¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • MAC-BAR(minimum alveolar concentration-blockade of autonomic response)
    ÀÚÀ²½Å°æ¾ïÁ¦ ÃÖ¼ÒÆóÆ÷³»³óµµ
  • MAC=> maximum allowable concentration
    ÃÖ´ëÇã¿ë³óµµ.
  • MAC=ÊÝmaximum allowable concentration
    ÃÖ´ëÇã¿ë³óµµ.
  • MCHC => mean cell hemogiooln concentration
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ
  • PCFIA => particle concentration fluorescence immunoassay
    ÀÔÀÚ³óÃàÇü±¤¸é¿ªÃøÁ¤(¹ý)
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • fractional concentration
    ºÐȹ³óµµ(ÝÂüñÒØÓø).
  • fractional concentration
    ºÐȹ³óµµ.
  • hemoglobin content/concentration
    Ç÷»ö¼ÒÇÔ·®/³óµµ
  • hydrogen ion concentration
    ¼ö¼ÒÀ̿³óµµ.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • plasma concentration
    Ç÷Àå³óµµ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cycle, life
    »ýȰ»ç, »ýȰÁÖ±â, »ýȰȯ
  • duration of life
    ¼ö¸í(ËÛËÎ).
  • effective half life
    À¯È¿¹Ý°¨±â.
  • effective half-life
    À¯È¿¹Ý°¨±â
  • elimination half-life
    ¼Ò½Ç¹Ý°¨±â.
  • embryonic life
    ¹èÅ»ýȰ(ÛÏ÷ÃßæüÀ).
  • expectancy of life
    ¿©¸í(ËçËÎ).
  • expectation of life
    ¿©¸í.
  • half-life
    ¹Ý°¨±â
  • intrauterine life
    Àڱó»»ýȰ(¡­ßæüÀ).
  • life annuity
    Á¾½Å¿¬±Ý(Ì¡ËàËçË»).
  • life change scale
    »ýȰº¯È­Ã´µµ(~ô©Óø)
  • life cycle
    »ýȰÁÖ±â
  • life cycle
    »ýȰÁÖ±â(~ñÎÑ¢)
  • life cycle
    »ýȰ»ç, »ýȰÁÖ±â, »ýȰȯ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • effective concentration
    À¯È¿ ³óµµ (êóüùÒØÓø)
  • enzyme concentration
    È¿¼Ò³óµµ (ý£áÈÒØÓø)
  • hydrogen ion concentration
    ¼ö¼Ò(â©áÈ)À̿ ³óµµ(ÒØÓø)
  • lethal concentration
    Ä¡»ç³óµµ(öÈÞÝÒØÓø)
  • maximum permissible concentration
    ÃÖ´ëÇã¿ë³óµµ(õÌÓÞúÉé»ÒØÓø)
  • normalized substrate concentration
    ³ë¸£¸» ±âÁú³óµµ(ѨòõÒØÓø)
  • osmotic concentration
    »ïÅõ³óµµ(ß¶÷âÒØÓø)
  • reduced substrate concentration
    ȯ»ê ±âÁú ³óµµ(üµß©Ñ¨òõÒØÓø)
  • relative substrate concentration
    »ó´ë ±âÁú³óµµ(ßÓÓßÐñòõÒØÓø)
  • saturating substrate concentration
    Æ÷È­ ±âÁú³óµµ(øéûùÐñòõÒØÓø)
  • second critical concentration
    Á¦(ð¯) 2 ÇѰè³óµµ(ùÚÍ£ÒØÓø)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
stat immediately [Lat. statim]; radiation emanation unit [German]
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
BNDD Bureau of Narcotics and Dangerous Drugs
DD dangerous drug; data definition; day of delivery; degenerated disc; degenerative disease; delusional...
DDA Dangerous Drugs Act; dideoxyadenosine; digital differential analysis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AQLQ Asthma Quality of Life Questionnaire
BLS Basic Life Support
CELSS Controlled Ecological Life Support System
DLQI Dermatology Life Quality Index
DALY Disability Adjusted Life Year
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • abridged life table
    °£ÀÌ »ý¸íÇ¥
  • advanced cardiac life support
    ÀÌÂ÷ ¼Ò»ý¼ú, ÀÌÂ÷ ½ÉÆó¼Ò»ý¼ú
  • aerospace life support system
    ¿ìÁÖ¿ë »ý¸í À¯Áö ½Ã½ºÅÛ
  • antibody half-life
    Ç×ü ¹Ý°¨±â
    Ç×ü ºÐÀÚ°¡ Çü¼ºµÈ ÈÄ Æò±Õ »ýÁ¸ÇÏ´Â ½Ã°£À» ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î¼­, º¸Åë µ¿¹°Ã¼³»¿¡¼­ ÀÏÁ¤·®ÀÇ ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 50%¸¦ Á¦°ÅÇÏ´Â µ¥ °É¸®´Â ½Ã°£À¸·Î Ç¥½ÃÇÑ´Ù. ÀÌ ¹Ý°¨±â´Â ¸é¿ª ±Û·ÎºÒ¸°ÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù.
  • average length of life
    Æò±Õ ¼ö¸í
  • cohort life table
    ÄÚȣƮ »ý¸íÇ¥
  • duration of life
    ¼ö¸í
  • elimination half-life
    ¼Ò½Ç ¹Ý°¨±â
  • expectancy of life
    ¿©¸í
  • fatigue life
    ÇÇ·Î ¼ö¸í
    ÇÇ·Î Æò°¡¹ýÀÇ Çϳª. ¹Ýº¹ ÀÀ·ÂÀÌ ÀÏÁ¤ÇÒ ¶§¿¡ ÆÄ±«¸¦ ÀÏÀ¸Å°´Â ÃÖ¼ÒÀÇ ¹Ýº¹ Ƚ¼ö.
  • half-life of immunoglobulin
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ ¹Ý°¨±â
  • life
    »ý¸í
    »ý¸í Çö»óÀÇ ÃÑĪ. À¯±âü°¡ ¹«±â¹°°ú´Â °ü°è¾ø´Â ÈûÀ̳ª ±â´ÉÀ» ³ªÅ¸³»´Â °æ¿ìÀÇ ¸·¿¬ÇÑ °³³ä. ÀϹÝÀûÀ¸·Î »ý¸íü´Â ¿©·¯ °¡Áö Á¤µµÀÇ Â÷ÀÌ´Â ÀÖÀ¸³ª ±â±¸È­, ÇÇÀڱؼº, ¿îµ¿, ¹ßÀ°, »ý½Ä, ÀûÀÀ µîÀÇ Æ¯Â¡À» ³ªÅ¸³½´Ù.
  • life cycle
    »ýȰȯ, »ýȰ ÁÖ±â
    »ý¹°ÀÇ »ýȰ»ç¿¡ ÀÖ¾î ÀÏ·ÃÀÇ Çö»ó.
  • life expectancy
    ¼ö¸í
    ¾î¶² ¿¬·É ¶Ç´Â ¿¬·ÉÃþÀÇ »ç¶÷ÀÌ ´õ »ì ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ´Â ¿¬¼ö·Î¼­ Åë°èÀûÀÎ Æò±Õ¿¡ ±âÃÊÇÑ °Í.
  • life habit
    »ýȰ ½À¼º, »ýȰ ½À°ü
    °°Àº »óȲ¿¡¼­ ¹Ýº¹µÈ ÇൿÀÇ ¾ÈÁ¤È­, ÀÚµ¿È­µÈ ¼öÇà. Á¼Àº Àǹ̷δ ¹Ýº¹¿¡ ÀÇÇÑ ±ÙÀ° ¿îµ¿À̳ª °Ç ¿îµ¿ÀÌ Á¤ÇüÈ­µÇ´Â °ÍÀ» ¸»ÇÏÁö¸¸, ÁÖ±âÀûÀ¸·Î ¹Ýº¹ÇÏ´Â ½Ä»ç³ª ¼ö¸é ½À°ü, dz¼Ó, ¹®È­ µî ³ÐÀº °ü½À¿¡ ´ëÇØ¼­µµ ½À°üÀ̶ó°í ÇÑ´Ù. ½À°üÀ̶õ Á¤ÇüÀûÀ̸ç ÀÚµ¿ÀûÀ¸·Î ¹ß»ýÇÏ´Â ¹ÝÀÀÀ̶ó´Â Á¡¿¡¼­ ÀÚÀ¯·ÎÀÌ º¯È­ÇÏ´Â ÀǵµÀû ¹ÝÀÀ°ú ±¸º°µÈ´Ù. ¶ÇÇÑ ½À°üÀº ½ÀµæµÈ °á°ú¶ó´Â Á¡¿¡¼­ ¼±ÃµÀû ¹ÝÀÀ°ú ±¸º°µÈ´Ù. ¼ú, ´ã¹è ¶Ç´Â ƯÁ¤ ¾à¹°ÀÇ »ó¿ëÀ̳ª, ¿­´ë, ÇÑ´ë¿¡¼­ÀÇ Àå±â »ýȰ, ¿ìÁÖºñÇà¿¡¼­ÀÇ ±â¾ÐÀ̳ª ¹«Áß·Â »óÅ¿¡ ´ëÇÑ ÀûÀÀ µî Ư¼öÇÑ ¿ÜÀûÀÎ »óȲ¿¡ ´ëÇÑ ¹ÝÀÀÀÇ Á¤ÇüÈ­´Â¡®¼øÈ­¡¯¶ó°í ÇÏ¿© ½À°ü°ú ±¸º°ÇÏ¿©¾ß ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
critical micelle concentration The concentration at which an amphipathic molecule (e.g., a phospholipid) will form a micelle.
(05 Mar 2000)
osmolar concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent.
(12 Dec 1998)
urinary concentration test A test of renal tubular function whereby the patient is dehydrated for a measured period of time and the specific gravity of the urine is subsequently determined.
(05 Mar 2000)
Fishberg concentration test A test of renal water conservation; after overnight fluid deprivation, morning urine samples are collected and specific gravity is measured.
(05 Mar 2000)
advanced life support Definitive emergency medical care that includes defibrillation, airway management, and use of drugs and medications.
Compare: basic life support.
(05 Mar 2000)
artificial life Artificial life (AL, alife) is a scientific discipline in whichresearchers study life by creating computer programs that recreatebiological systems from scratch.
(09 Oct 1997)
basic life support Emergency cardiopulmonary resuscitation, control of bleeding, treatment of shock, acidosis, and poisoning, stabilization of injuries and wounds, and basic first aid.
(05 Mar 2000)
biological half-life <biochemistry, biology> This is the time required for one-half of the total amount of a particular substance in a biological system to be consumed or broken down by biological processes when the rate of removal is approximately exponential.
Toxic chemicals with a long biological half-life (such as some pesticides) will tend to accumulate in the body and are, therefore, more likely to be harmful. A substance with a short biological half-life may still accumulate if a portion of it it becomes tightly bound to bone or other tissues, even if most of it is quickly cleared from the body.
(21 Mar 1998)
vegetative life The simple metabolic and reproductive activity of humans or animals, apart from the exercise of conscious mental or psychic processes.
(05 Mar 2000)
germ-free life Animals not contaminated by or associated with any foreign organisms.
(12 Dec 1998)
change of life Colloquialism for menopause, climacteric.
(05 Mar 2000)
RNA life <biology, molecular biology> A hypothetical life form lacking DNA and protein which may have existed on early earth and in which RNA served both a genetic coding and a catalytic function.
(23 Aug 1998)
physical half-life The time required for half the atoms of a radionuclide to undergo disintegration.
(05 Mar 2000)
wrongful life In civil law a cause of action which alleges that a defendant has wrongfully caused a child to be born.
(12 Dec 1998)
postnatal life That interval of life after birth; in man, usually divided into periods: neonatal, infancy, childhood, adolescence, and adulthood.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • family life cycle
    °¡Á· ÁÖ±â
  • future life
    Àú¼¼»ó;³»¼¼;¿µ°è
  • good life
    Æò±Õ ¼ö¸í±îÁö »ì °¡¸ÁÀÌ ÀÖ´Â »ç¶÷
  • half life
    (¹Ý»ç´É)¹Ý°¨±â
  • high life
    »ó·ù »çȸ(ÀÇ »ýȰ)
  • industrial life insurance
    ³ëµ¿ÀÚ »ý¸íº¸Çè;°£ÀÌ »ý¸íº¸Çè
  • life
    »ý¸í;¸ñ¼û;»ý¾Ö;ÀÏ»ý;»ý±â;Ȱ·Â;Àü±â;º»ÀÎ;as large(big)as ~ ½Ç¹° Å©±âÀÇ;Ʋ¸²¾øÀÌ;come(bring)to ~ ¼Ò»ýÇÏ´Ù(½ÃŰ´Ù)
  • life Guards
    ±ÙÀ§ ±âº´ ¿¬´ë
  • life annuity
    Á¾½Å¿¬±Ý
  • life assurance
    »ý¸íº¸Çè
  • life belt
    ±¸¸í´ë
  • life buoy
    ±¸¸í ºÎ³¶
  • life expectancy
    Æò±Õ ¿¹»ó ¼ö¸í
  • life force
    =ELAN VITAL
  • life history
    ÀÏ»ý;»ý¾Ö;(°³Ã¼ÀÇ ¹ß»ý¿¡¼­ Á×À½±îÁöÀÇ)»ýȰ»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á